C12N 2795/14222
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2795/14222 (New viral proteins or individual genes, new structural or functional aspects of) appears on 5 US grants and 9 published applications in this corpus.
Search patents in C12N- Granted patents
- 5
- Published applications
- 9
- Assignees
- 6
- Inventors
- 23
- Latest grant
- 8 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 1 | 1 |
| 2019 | 0 | 0 |
| 2020 | 1 | 0 |
| 2021 | 0 | 2 |
| 2022 | 0 | 2 |
| 2023 | 0 | 0 |
| 2024 | 0 | 1 |
| 2025 | 1 | 0 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Programmable bacteria for the treatment of cancer8 Jul 2025US 12,350,297 B2National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS)
- Fed-batch process for the production of bacterial ghosts7 Jan 2020US 10,526,574 B2Bird-C GmbH
- Methods and systems for engineering bacterial systems to shield toxicity during non-native protein expression and purification18 Dec 2018US 10,155,951 B2Lawrence Livermore National Security, LLC
- Phage-resistant streptococcus16 Jun 1998US 5,766,904 ANestec S. A.
- Bacteriophage of chlamydia psittaci21 Apr 1998US 5,741,697 AUniversity of Rochester
- Programmable Bacteria for the Treatment of Cancer8 Jan 2026US 2026/0007703 A1The Trustees of Columbia University in the City of New York
- Amurins lysins, and lysin-antimicrobial peptide (amp) constructs active against gram-negative bacteria6 Jun 2024US 2024/0181022 A1
- Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof29 Dec 2022US 2022/0411473 A1
- Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative and acid-fast bacteria22 Dec 2022US 2022/0401514 A1
- Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria28 Oct 2021US 2021/0330738 A1
Most cited
By later US patents
- Methods and systems for engineering bacterial systems to shield toxicity during non-native protein expression and purification1US 10,155,951 B2Lawrence Livermore National Security, LLC · 2018
- Bacteriophage of chlamydia psittaci1US 5,741,697 AUniversity of Rochester · 1998
- Phage-resistant streptococcus1US 5,766,904 ANestec S. A. · 1998